Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

447 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Association of serum markers with improvement in clinical response measures after treatment with golimumab in patients with active rheumatoid arthritis despite receiving methotrexate: results from the GO-FORWARD study.
Visvanathan S, Rahman MU, Keystone E, Genovese M, Klareskog L, Hsia E, Mack M, Buchanan J, Elashoff M, Wagner C. Visvanathan S, et al. Among authors: keystone e. Arthritis Res Ther. 2010;12(6):R211. doi: 10.1186/ar3188. Epub 2010 Nov 17. Arthritis Res Ther. 2010. PMID: 21083889 Free PMC article. Clinical Trial.
Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years.
Rahman MU, Buchanan J, Doyle MK, Hsia EC, Gathany T, Parasuraman S, Aletaha D, Matteson EL, Conaghan PG, Keystone E, van der Heijde D, Smolen JS. Rahman MU, et al. Among authors: keystone e. Ann Rheum Dis. 2011 Sep;70(9):1631-40. doi: 10.1136/ard.2010.146043. Epub 2011 Jun 27. Ann Rheum Dis. 2011. PMID: 21708910 Free PMC article. Review.
Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study.
Keystone EC, Genovese MC, Klareskog L, Hsia EC, Hall ST, Miranda PC, Pazdur J, Bae SC, Palmer W, Zrubek J, Wiekowski M, Visvanathan S, Wu Z, Rahman MU; GO-FORWARD Study. Keystone EC, et al. Ann Rheum Dis. 2009 Jun;68(6):789-96. doi: 10.1136/ard.2008.099010. Epub 2008 Dec 9. Ann Rheum Dis. 2009. PMID: 19066176 Free PMC article. Clinical Trial.
Golimumab 3-year safety update: an analysis of pooled data from the long-term extensions of randomised, double-blind, placebo-controlled trials conducted in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.
Kay J, Fleischmann R, Keystone E, Hsia EC, Hsu B, Mack M, Goldstein N, Braun J, Kavanaugh A. Kay J, et al. Among authors: keystone e. Ann Rheum Dis. 2015 Mar;74(3):538-46. doi: 10.1136/annrheumdis-2013-204195. Epub 2013 Dec 16. Ann Rheum Dis. 2015. PMID: 24344160 Free PMC article. Clinical Trial.
The effect of golimumab on haemoglobin levels in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.
Furst DE, Kay J, Wasko MC, Keystone E, Kavanaugh A, Deodhar A, Murphy FT, Magnus JH, Hsia EC, Hsu B, Xu S, Rahman MU, Doyle MK. Furst DE, et al. Among authors: keystone e. Rheumatology (Oxford). 2013 Oct;52(10):1845-55. doi: 10.1093/rheumatology/ket233. Epub 2013 Jul 9. Rheumatology (Oxford). 2013. PMID: 23838027 Free PMC article.
447 results